

Technology Appraisal Committee Meeting (Committee [D])

Minutes: Confirmed

Date and Time: Tuesday 16 April 2019 10:15 to 17:33

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:

1. Professor Gary McVeigh (Chair)	Present for all notes
2. Dr Lindsay Smith (Vice Chair)	Present for all notes
3. Nabeel Alsindi	Present for all notes
4. James Avery	Present for all notes
5. Professor David Bowen	Present for all notes
6. Professor Rachel Elliott	Present for all notes
7. Professor Paula Ghaneh	Present for all notes
8. Rebecca Harmston	Present for all notes
9. Dr Andrew Hitchings	Present for all notes
10. Dr Robert Hodgson	Present for all notes
11. Dr Bernard Khoo	Present for all notes
12. Olaolu Oloyede	Present for all notes
13. Dr Malcolm Oswald	Present for all notes
14. James Avery	Present for all notes
15. Dr Paula Parvulescu	Present for all notes

In attendance:

Aline Navega Biz	ERG representative, School of Health and Related Research (SchARR)	Present from notes 5 to 13
Rebecca Bouch	Administrator, National Institute for Health and Care Excellence	Present for all notes
Sarah Broderick	Patient Expert, nominated by the Migraine Trust	Present from notes 17 to 25
Zameel Cader	Clinical Expert, nominated by Novartis	Present from notes 17 to 25
Professor Peter Clark	CDF Clinical Lead, NHS England	Present from notes 5 to 16
Robert Danby	Clinical Expert, nominated by Anthony	Present from notes 29 to 37

	Nolan	
Joanne Ekeledo	Project Manager, National Institute for Health and Care Excellence	Present from notes 17 to 28
Dr Alistair Greystoke	Clinical Expert, nominated by Merck Sharp & Dohme	Present for notes 5 to 13
Nicola Hay	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 29 to 41
Jasdeep Hayre	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Dr Robert Hodgson	ERG representative, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present from notes 29 to 37
Caron Jones	Technical Advisor, National Institute for Health and Care Excellence	Present for all notes
David Kernick	Clinical Expert, nominated by British Association for the Study of Headaches	Present from notes 17 to 25
Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Victoria Kelly	Technical Advisor, National Institute for Health and Care Excellence	Present from notes 17 to 28
Linda Landells	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Alan Moore	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 17

Omar Moreaa	Technical Analyst, National Institute for Health and Care Excellence	Present from notes 17 to 28
Thomas Paling	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 29 to 41
Karl Peggs	Clinical Expert, nominated by Merck Sharp & Dohme	Present from notes 29 to 37
Bradley Price	Patient Expert, nominated by Anthony Nolan	Present from notes 29 to 37
Bram Ramaekers	ERG representative, Kleijnen Systematic Reviews	Present from notes 17 to 25
Steve Rothberg	Patient Expert, nominated by Anthony Nolan	Present from notes 29 to 37
Paul Tappenden	ERG representative, School of Health and Related Research (SchARR)	Present from notes 5 to 13
Wendy Thomas	Patient Expert, nominated by the Migraine Trust	Present from notes 17 to 25
Lesley Uttley	ERG representative, School of Health and Related Research (SchARR)	Present from notes 5 to 13
Marie Westwood	ERG representative, Kleijnen Systematic Reviews	Present from notes 17 to 25

Non-public attendees:

Sohaib Ashraf	Technical Analyst, National Institute for Health and Care Excellence	Present for notes all notes
Adam Brookes	Technical Analyst, National Institute for Health and Care Excellence	Present for notes all notes

Luke Cowie	Technical Analyst, National Institute for Health and Care Excellence	Present for notes all notes
Rebecca Fletcher	Public Health Registrar, National Institute for Health and Care Excellence	Present for notes all notes
James Hall	Senior Medical Editor, National Institute for Health and Care Excellence	Present for notes all notes
Joanna Perkin	Publishing Team, National Institute for Health and Care Excellence	Present for notes all notes
Mandy Tonkinson	PIP, National Institute for Health and Care Excellence	Present for notes all notes
Maroulla Whitely	RIA, National Institute for Health and Care Excellence	Present for notes all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1306], erenumab for preventing migraine [ID1188] and letermovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant [ID1153].
2. The Chair informed the Committee of the non-public observers at this meeting: Sohaib Ashraf, Adam Brookes, Luke Cowie, Rebecca Fletcher, James Hall, Joanna Perkin, Mandy Tonkinson and Maroulla Whitely.
3. Apologies were received from Gillian Ells, Dr Peter Hall, Dr Soo Fon Lim, Dr Guy Makin and Professor David Meads.

Any other Business

4. None.

Appraisal of Pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1306]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Alistair Greystoke, Yvonne Summers and Professor Peter Clark to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Merck Sharp & Dohme to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Lindsay Smith (Vice Chair), Nabeel Alsindi, James Avery, Professor David Bowen, Professor Rachel Elliott, Professor Paula Ghaneh, Rebecca Harmston, Dr Andrew Hitchings, Dr Robert Hodgson, Dr Bernard Khoo, Olaolu Oloyede, Dr Malcolm Oswald, James Avery and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1306].
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1306]
9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1306]
10. The Chair introduced the lead team, Nabeel Alsindi, Paula Parvulescu and Rebecca Harmston who gave presentations on the clinical effectiveness and cost effectiveness of pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1306].
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to

Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. The committee discussed confidential information submitted by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1306].
 - 15.1. The committee decision was based on consensus.
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of Erenumab for preventing migraine [ID1188]

Part 1 – Open session

17. The Chair welcomed the invited experts: Sarah Broderick, Zameel Cader, David Kernick and Wendy Thomas to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from Novartis to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
 - 19.1. Dr Lindsay Smith (Vice Chair), Nabeel Alsindi, James Avery, Professor David Bowen, Professor Rachel Elliott, Professor Paula Ghaneh, Rebecca Harmston, Dr Andrew Hitchings, Dr Robert Hodgson, Dr Bernard Khoo, Olaolu Oloyede, Dr Malcolm Oswald, James Avery and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Erenumab for preventing migraine [ID1188].
20. The Chair asked all NICE Staff to declare any relevant interests.
 - 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of erenumab for preventing migraine [ID1188].
21. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
 - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial

interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of erenumab for preventing migraine [ID1188].

22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. The committee discussed confidential information submitted by the company.
27. The Committee continued to discuss the clinical and cost effectiveness of Erenumab for preventing migraine [ID1188].
28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of Letemovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant [ID1153]

Part 1 – Open session

29. The Chair welcomed the invited experts: Robert Danby, Karl Peggs, Bradley Price and Steve Rothberg to the meeting and they introduced themselves to the Committee.
30. The Chair welcomed company representatives from Merck Sharp & Dohme to the meeting.
31. The Chair asked all Committee members to declare any relevant interests
 - 31.1. Dr Lindsay Smith (Vice Chair), Nabeel Alsindi, James Avery, Professor David Bowen, Professor Rachel Elliott, Professor Paula Ghaneh, Rebecca Harmston, Dr Andrew Hitchings, Dr Robert Hodgson, Dr Bernard Khoo, Olaolu Oloyede, Dr Malcolm Oswald, James Avery and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of

letermovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant [ID1153].

32. The Chair asked all NICE Staff to declare any relevant interests.
 - 32.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of letermovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant [ID1153].
33. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
 - 33.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of letermovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant [ID1153].
34. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
35. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
36. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
37. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

38. The committee discussed confidential information submitted by the company.
39. The Committee continued to discuss the clinical and cost effectiveness of letermovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant [ID1153].
40. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

41. Thursday 23 May, 10:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.